Medplus Health Q3 FY26 Earnings Analysis

Published 5 Aug 2026 | Retailing | Market Cap: ₹8.3K Cr

Price

690

Market Cap

₹8.3K Cr

P/E Ratio

39.4

Earnings Summary

- MedPlus expects gradual growth in same-store sales growth (SSSG), targeting high-single digit growth (9-10%) within the next 2 years. - MedPlus expects same-store sales growth (SSSG) to gradually improve to high-single digits (9%-10%) within the next 2 years.

📊 Revenue & Sales Performance

- MedPlus expects gradual growth in same-store sales growth (SSSG), targeting high-single digit growth (9-10%) within the next 2 years. - The company aims to continue adding 600 to 1,000 stores annually, including a mix of owned and franchisee stores. - Private label non-pharma category is growing steadily due to improved store layouts and increased impulsive buying. - Revenue growth is supported by deepening presence in southern and eastern India, with initial expansion into states like Chhattisgarh and Madhya Pradesh. - Diagnostics segment is currently a small part (<2%) and will expand only after crossing subscription thresholds. - Overall pharmacy revenue grew 8.8% Y-o-Y on GMV basis in the recent quarter. - The company is cautious in its near-term outlook but optimistic about achieving higher growth rates as operational efficiencies and store maturity improve.

📈 Profitability & Margins

- MedPlus expects same-store sales growth (SSSG) to gradually improve to high-single digits (9%-10%) within the next 2 years. - Store network expansion is planned with annual addition of 600 to 1,000 stores, including both owned and franchisee formats, supporting top-line growth. - Operating EBITDA margin for pharmacy retail is expected to be stable with slight improvements; no significant jump anticipated in the near term. - Employee expenses growth, driven by retention schemes, is expected to moderate going forward. - Focus remains on balancing growth and margin maintenance, with cautious outlook on immediate double-digit growth in profits despite pharma market growth at ~8%. - Diagnostic segment currently small (<2% revenue), with no major capex expansion planned till desired subscription targets are met. - Overall profitable growth targeted through store expansion, deeper market penetration especially in Southern and Eastern India, and increased private label sales.

🏗️ Capital Expenditure Plans

- Diagnostics segment: No immediate expansion planned until subscription numbers cross 250,000. - Current diagnostic capex: INR 120+ crores spent to set up 12 diagnostic centers, including 4 large centers. - Future diagnostics expansion: On hold until better subscription numbers are achieved. - Store network expansion: Planning to add 600 to 1,000 stores annually (including franchisees). - Franchisee model: Still in pilot phase; future growth dependent on franchisee adoption. - Supply chain: New warehouses added and functional to improve fill rates. - Property bank: Holding 400+ locations for future store launches; pre-operative costs associated with these. - No major new capex in diagnostics planned currently; focus remains on optimizing existing assets and measured store/network expansion.

💰 Fundraising & Capital Structure

- There is no specific mention of any current or planned fundraising through debt or equity in the provided transcript. - The company has sufficient cash reserves, as indicated by the statement "the fact that we have money in the bank." - Expansion plans, such as opening 600 to 1,000 stores annually and franchisee growth, appear to be funded internally or through existing resources. - No direct references to new debt or equity issuances were made during the call or Q&A. - Management has requested more time to provide detailed plans on growth strategies, which might include funding, but no concrete fundraising plans were disclosed as of now.

📋 Order Book & Pipeline

The transcript provided does not specifically mention details about the current or expected order book or any pending orders for MedPlus Health Services Limited. The focus is mainly on operational performance, store expansions, inventory, margins, competition, and financial metrics. Key highlights related to growth and expansion are: - Plans to add 600 new stores in fiscal year 2026, including franchisee stores. - Network grew to 4,930 stores as of the quarter. - No direct details on order books or pending purchase orders mentioned. - Expansion focus primarily in southern and eastern India; limited or no direct expansion yet in northern India. - Working capital and inventory management discussed, but no pending orders highlighted. If you have more specific queries or documents about orders, please provide them for detailed insights.

Key Metrics

Frequently Asked Questions

What were Medplus Health Q3 FY26 results?

- MedPlus expects gradual growth in same-store sales growth (SSSG), targeting high-single digit growth (9-10%) within the next 2 years. - MedPlus expects same-store sales growth (SSSG) to gradually improve to high-single digits (9%-10%) within the next 2 years.

What is Medplus Health share price analysis?

Medplus Health currently shows a neutral. The stock trades at a P/E of 39.4 with a market cap of ₹8,300. Investors should review the full earnings analysis for detailed insights.

Is Medplus Health planning capital expenditure?

- Diagnostics segment: No immediate expansion planned until subscription numbers cross 250,000.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

What Medplus Health Services Ltd's management said in earlier quarters

Others in Retailing this season

  • Crizac Ltd (Q3 FY26)

    Crizac Q3 FY26 quarterly results analysis. - The company expects a growth of around 25%-30% in revenue for the current year, with the possibility of slightly ex

  • Vishal Mega Mart Ltd (Q3 FY26)

    Vishal Mega Mart Ltd Q3 FY26 quarterly results analysis. - Vishal Mega Mart is optimistic about future growth due to GST rationalization, income tax rate cuts,

  • Swiggy Ltd (Q3 FY26)

    Swiggy Ltd Q3 FY26 quarterly results analysis. - The current store network can support double the orders, with expected capacity to be reached within about a ye

  • Brainbees Solutions Ltd (Q3 FY26)

    Brainbees Solutions Ltd Q3 FY26 quarterly results analysis. No information is provided regarding the same in the latest conference call. Market Cap ₹11,241, P/E